The US Food and Drug Administration will be approving the Pfizer/BioNTech vaccine for children aged 12 to 15 next week, according to a report on Tuesday.
The vaccine was found to be 100% effective in the age group at the clinical trials.
As reported by CNN the FDA is currently overviewing the data provided by Pfizer about the vaccine and is set to amend its emergency use criteria from over 16 to over 12.
Pfizer and its German partner BioNTech announced on March 31 its coronavirus vaccine BNT162b2 demonstrated 100% efficacy and robust antibody responses among 12 to 15 years of age in a Phase 3 trial that included 2,260 adolescents.
/Next-COVID-Strain.jpeg "People walk past an advertisement warning about COVID-19 in Manchester, England, on Saturday. (Photo: Reuters)")
/COVID-Global-Emergency-WHO.webp "Millions of cases are being reported each week, but surveillance has declined, making it difficult to get a full overview of the situation and how the virus is mutating. (Photo: Reuters)")
/WHO-COVID-END.jpg "Tedros Adhanom Ghebreyesus, Director General of WHO, speaks with Charles Michel, EU Council President, during the G7 leaders summit at Castle Elmau in Kruen, Germany, on Monday, June 27, 2022. (Michael Kappeler/Pool via AP)")
/Monkeypox-Outbreak-Health-Emergency.jpg "Daniel Rofin, 41, receives a vaccine against Monkeypox from a health professional in medical center in Barcelona. (Photo: AP)")
/South-American-Monkeypox-Cases.webp "The monkeypox virus has been found in 78 countries since early May according to the WHO [File: Rick Bowmer/AP Photo]")
/Global-Health-Emergency-Monkeypox.jpg "Test tubes labelled \"Monkeypox virus positive\" are seen in this illustration taken May 22, 2022. (Photo: Reuters/Dado Ruvic)")
